Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERV
2024-515418-41-00Phase 3Completed
- Sponsor
- ASL Biella
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palivizumab in respiratory syncytial virus bronchiolitis, pulmonary infection, recurrent wheeze and 1 more (2 arms), sponsored by ASL Biella. Primary endpoint: Overall respiratory morbidity (composite primary endpoint). Started Aug 2024; status: completed.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus bronchiolitispulmonary infectionrecurrent wheezeasthma
Beyond the preview
Go deeper on 2024-515418-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515418-41-00.